Dr. Carlo Aschele - E.O. Ospedali Galliera, Italy
ASCO press conference: Adding oxaliplatin (Eloxatin) to standard treatment in
patients with locally advanced rectal cancer does not improve tumour response. A preliminary analysis, however, suggests the treatment may reduce distant metastases.